Nature Reviews Clinical Oncology

Scope & Guideline

Exploring Breakthroughs in Clinical Oncology

Introduction

Welcome to the Nature Reviews Clinical Oncology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Nature Reviews Clinical Oncology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1759-4774
PublisherNATURE PORTFOLIO
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2009 to 2024
AbbreviationNAT REV CLIN ONCOL / Nat. Rev. Clin. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

Nature Reviews Clinical Oncology focuses on providing comprehensive insights into the rapidly evolving field of clinical oncology, emphasizing the latest advancements in cancer treatment and management.
  1. Translational Oncology:
    The journal aims to bridge the gap between laboratory research and clinical practice, highlighting studies that translate basic scientific discoveries into innovative cancer therapies.
  2. Multidisciplinary Approaches:
    Nature Reviews Clinical Oncology encompasses a wide range of disciplines, including medical oncology, surgical oncology, radiation oncology, and palliative care, fostering integrated strategies for cancer treatment.
  3. Patient-Centered Care:
    The journal promotes research that prioritizes patient outcomes, quality of life, and the importance of personalized treatment plans tailored to individual patient needs.
  4. Emerging Therapeutics:
    A key focus is on the development and evaluation of novel therapeutic agents, including immunotherapies, targeted therapies, and combination strategies that enhance treatment efficacy.
  5. Biomarkers and Precision Medicine:
    The journal emphasizes the role of biomarkers in predicting treatment responses and guiding personalized medicine approaches in oncology.
  6. Clinical Trials and Evidence-Based Practice:
    Nature Reviews Clinical Oncology publishes insights on clinical trial findings, offering evidence-based recommendations for current and future cancer treatment protocols.
Nature Reviews Clinical Oncology is at the forefront of several emerging themes in oncology research, reflecting the dynamic nature of the field and the ongoing quest for improved cancer therapies.
  1. Immunotherapy Advances:
    Immunotherapy continues to be a major focus, with increasing publications on novel immune checkpoint inhibitors, CAR T-cell therapies, and combination strategies that enhance immune responses against tumors.
  2. Precision Oncology:
    There is a growing emphasis on precision oncology, utilizing genomic profiling to tailor treatments to individual patients based on their unique tumor characteristics.
  3. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning in oncology is emerging as a significant trend, with research exploring their applications in diagnostics, treatment planning, and predicting patient outcomes.
  4. Microbiome Research in Cancer:
    Studies investigating the role of the microbiome in cancer development and treatment response are gaining traction, highlighting its potential impact on immunotherapy efficacy.
  5. Patient-Centered Research:
    There is a notable increase in research focusing on patient-centered outcomes, quality of life, and the psychosocial aspects of cancer care, reflecting a holistic approach to oncology.

Declining or Waning

While Nature Reviews Clinical Oncology continues to evolve, certain themes have shown a decline in focus over recent years, reflecting shifts in research priorities and clinical practice.
  1. Traditional Chemotherapy:
    There has been a noticeable decrease in the emphasis on traditional chemotherapy regimens, as newer targeted therapies and immunotherapies gain prominence in clinical practice.
  2. Single-Agent Therapies:
    Research into single-agent therapies is becoming less frequent, with a greater focus on combination therapies that leverage multiple mechanisms of action to improve patient outcomes.
  3. Generalized Treatment Protocols:
    The trend is moving away from one-size-fits-all treatment approaches, with less emphasis on generalized protocols in favor of personalized treatment plans tailored to specific patient profiles.

Similar Journals

CHEMOTHERAPY

Exploring Breakthroughs in Drug Discovery and Oncology
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Therapeutic Advances in Medical Oncology

Transforming oncology with groundbreaking discoveries.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

JCO Precision Oncology

Fostering Breakthroughs in Individualized Cancer Treatments
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

CANCER TREATMENT REVIEWS

Fostering collaboration in the fight against cancer.
Publisher: ELSEVIER SCI LTDISSN: 0305-7372Frequency: 10 issues/year

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Clinical Genitourinary Cancer

Transforming insights into clinical practice.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Molecular and Clinical Oncology

Connecting researchers to revolutionize cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

ONCOLOGY

Advancing cancer research through impactful insights.
Publisher: KARGERISSN: 0030-2414Frequency: 12 issues/year

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Surgical Oncology Clinics of North America

Your Gateway to Surgical Oncology Expertise
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

CURRENT TREATMENT OPTIONS IN ONCOLOGY

Navigating the Evolving Landscape of Cancer Care
Publisher: SPRINGERISSN: 1527-2729Frequency: 12 issues/year

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.

Tumori Journal

Empowering Oncology Through Innovative Discoveries.
Publisher: SAGE PUBLICATIONS LTDISSN: 0300-8916Frequency: 6 issues/year

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.